SCHEMBL19743600

SCHEMBL19743600

O=C(O)NCCOc1cccc(N2CCCC2)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.48
ADRA1A P35348 1/20 0.48
ALDH1A1 P00352 4/20 0.46
MAPT P10636 2/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTR2A P28223 3/20 0.44
DRD3 P35462 3/20 0.44
HSD11B1 P28845 2/20 0.43
KLKB1 P03952 1/20 0.42
PDE10A Q9Y233 5/20 0.42
HTR2C P28335 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGDR Q13258 1/20 0.41
CNR1 P21554 2/20 0.40
TGM2 P21980 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19743952 0.78 HTR1A (0.49) HTR1AADRA1AALDH1A1KLKB1LMNA
SCHEMBL21383930 0.76 MTNR1A (0.44) HTR1AADRA1AALDH1A1MAPTLMNA
Hydrochloric Acid SCHEMBL19743621 0.75 CXCR4 (0.43) HTR1AADRA1APDE10A
SCHEMBL16061881 0.75 HTR7 (0.51) ALDH1A1MAPTSMN1; SMN2
SCHEMBL19743601 0.75 HTR1A (0.43) HTR1AADRA1AALDH1A1MAPTSMN1; SMN2
SCHEMBL1728737 0.74 HSD11B1 (0.49) HSD11B1
SCHEMBL1263372 0.72 HRH4 (0.49) ALDH1A1MAPTHTTHTR2APDE10A
SCHEMBL30440467 0.72 HRH4 (0.49) ALDH1A1MAPTHTTHTR2APDE10A
SCHEMBL19743711 0.72 HTR1A (0.44) HTR1AADRA1AALDH1A1MAPTHTT
SCHEMBL28670305 0.72 HTR1A (0.62) HTR1AADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3475268-B9 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2021-04-21 EP disclosed
EP-3475268-B1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2020-08-19 EP disclosed
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors NEUROLIXIS (FR) 2020-02-18 US disclosed
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2019-06-27 US disclosed
EP-3475268-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS Neurolixis (FR) 2019-05-01 EP disclosed
WO-2017220799-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors HTR5A, HTR1A, HTR1E HTR1A 2/4885ADRA1A 18/4885ALDH1A1 1612/4885
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS HTR5A, HTR1A, HTR1E HTR1A 2/4885ADRA1A 18/4885ALDH1A1 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.